New treatment strategies have focused on both dipeptidyl peptidase (DPP)-4 inhibitors, and SGLT-2’s.
Read More »The Dual Role of Sitagliptin in Improving Cognitive Function and Glycemic Control
Study conducted in mice has shown that sitagliptin might offer beneficial effects in reversing cognitive impairment… Alzheimer’s disease (AD) is the most common form of dementia. Symptoms progress slowly and worsen over time resulting in interference with common daily activity. There is no known cure of AD, but the use …
Read More »Practical Diabetes Care, 3rd Ed., Excerpt #9: Pharmacological Treatment of Hyperglycemia Part 2 of 2
David Levy, MD, FRCP Drugs acting on the incretin system (entero-insular axis) (Fig. 6.2) The incretin effect Bayliss and Starling inferred the existence of gut-derived substances affecting carbohydrate metabolism more than a century ago, but the incretin effect was not described until 1969: the observation that for a given achieved level …
Read More »DPP-4 Inhibitor Saxagliptin May Slow Beta-cell Decline in Type 2
A multinational team of researchers studied data from over 16,000 patients in the SAVOR-TIMI 53 trial…. Saxagliptin (Onglyza) is a commonly prescribed dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. An international team of researchers examined the effects of saxagliptin on glycemic stability and β-cell function in the …
Read More »Practical Diabetes Care, 3rd Ed., Excerpt #8: Pharmacological Treatment of Hyperglycemia Part 1 of 2
David Levy, MD, FRCP Introduction The pharmacological management of blood glucose in type 2 diabetes remains the most contentious area of diabetes management, and although until relatively recently in the USA the only agents to treat blood glucose were insulin and sulphonylureas, this limited repertoire in no way inhibited the controversy, …
Read More »PPAR Agonists Raise Heart Failure Risk for Pre-diabetic and T2DM Patients
In the meta-analysis of 14 randomized trials, DPP-4 inhibitors were also found to increase cardiovascular risk slightly while the effect of insulin glargine was neutral…. Data was reviewed from 14 randomized controlled trials of 95,502 patients with or at risk for type 2 diabetes taking new or more intensive glucose-lowering …
Read More »Practical Diabetes Care, 3rd Ed., Excerpt #7: Type 2 Diabetes: General Introduction Part 2 of 2
David Levy, MD, FRCP General Recommendations on Macronutrients Carbohydrate Recommended daily allowance is about 130 g. Low glycemic index foods (e.g. barley, oats, beans, lentils, rye bread) can reduce HbA1c by about 0.4% (4 mmol/mol) compared with high glycemic index foods. More importantly, high whole-grain, cereal fiber, bran and germ intake …
Read More »Reduced GLP-1 Precedes Type 2 Diabetes
This might be a reason not to use a DPP-4 for those with long standing diabetes… Reduction in the glucose-regulating hormone glucagon-like peptide-1 (GLP-1) appears to occur before the development of type 2 diabetes and obesity, according to new published research. Investigator Kristine Færch, PhD, senior research fellow at the …
Read More »DPP-4 Inhibitors Protect against Hypoglycemia
Mice treated with DPP-4 inhibitors also showed an increase in production of their own glucagon… Siri Malmgren, a researcher at Lund University, stated that, “If these inhibitors also prove effective in humans against low blood sugar, then this supports the idea that the area of application of these drugs could …
Read More »FDA Approves Empagliflozin/Linagliptin Combination Glyxambi
Approved as an adjunctive treatment to diet and exercise for adults with type 2 diabetes… The once-daily tablet is the first in the United States to combine a sodium glucose cotransporter 2 (SGLT2) inhibitor (empagliflozin) with a dipeptidyl peptidase-4 (DPP-4) inhibitor (linagliptin). The tablets contain 10 or 25 mg of …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.